The long-term horizon: Patients who will remain untreated in the era of triple therapy†

Hepatitis C viral infection in incarcerated patients

“…Although the treatment of HCV infections in the prisoner population provides an opportunity to make a significant improvement to public health, therapy for HCV among incarcerated patients presents several challenges that make patients in departments of corrections (DOCs) one of the difficult‐to‐treat groups (as discussed by Aronsohn and Jensen in the first issue of Clinical Liver Disease 5). For example, psychiatric side effects were reported in up to 31% of the subjects enrolled in the registration trials of pegylated interferon‐α and ribavirin 6, 7.…”